Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M35.4Revenue $M0Net Margin (%)0Z-Score-5.3
Enterprise Value $M10.8EPS $-1.2Operating Margin %0F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %-16.0Quick Ratio15.4Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %-32.2Current Ratio15.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-44.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-53.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.5ROI % (ttm)-70.8Gross Margin Increase y-yN

Gurus Latest Trades with BIOD

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIODDavid Swensen 2010-12-31 Sold Out $6.44 - $19.08
($10.24)
$ 1.51-85%Sold Out0
BIODDavid Swensen 2009-12-31 Buy 11.73%$14.16 - $21.04
($16.88)
$ 1.51-91%New holding, 903400 sh.903,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIOD is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BIOD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LIEBERMAN IRADirector 2013-12-20Buy10,800$2.29-34.06view
Pereira Brian JGDirector 2013-12-20Sell4,734$2.26-33.19view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-12-07Sell12,256$2.8-46.07view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-11-02Sell3,500$2.81-46.26view
Krasner Alan SethChief Medical Officer 2012-11-02Sell3,500$2.81-46.26view
DESOUZA ERROL BCEO 2012-09-20Buy10,000$3.34-54.79view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-03-13Sell2,096$2.36-36.02view
Pereira Brian JGDirector 2011-12-16Sell3,750$2.6-41.92view
Steiner SolomonDirector 2011-09-26Sell32,695$4.36-65.37view
Steiner SolomonDirector 2011-09-21Sell79,129$4.72-68.01view

Press Releases about BIOD :

    Quarterly/Annual Reports about BIOD:

    News about BIOD:

    Articles On GuruFocus.com
    cooldecency99 note on BIOD May 01 2010 
    Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
    Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
    Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
    Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
    Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 


    More From Other Websites
    Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog Jan 28 2015
    Nasdaq stocks posting largest volume increases Jan 28 2015
    NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog Jan 27 2015
    Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst Blog Jan 27 2015
    Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog Jan 26 2015
    Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Jan 23 2015
    UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Jan 22 2015
    Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Jan 21 2015
    CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog Jan 21 2015
    Immunomedics Reports Data on Oncology Candidate - Analyst Blog Jan 21 2015
    ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog Jan 21 2015
    Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog Jan 20 2015
    UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog Jan 19 2015
    Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Jan 15 2015
    Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog Jan 15 2015
    US pre-open: Futures rise on wake of dovish Fed comment Jan 08 2015
    Wednesday's After-Hours Movers Jan 07 2015
    BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 07 2015
    Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to... Jan 07 2015
    BIODEL INC Financials Dec 30 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK